ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ALXO vs WHWK // ALTMAN Z-SCORE & DEBT/EQUITY

ALX Oncology Holdings Inc. (NASDAQ) VS. Whitehawk Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ALXO 2 — WHWK 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALXO VS. WHWK) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ALXO WHWK SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 89.40% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — -65.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE — 3.11 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 3/9 +1.00 ALXO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 56.4 39.2 +17.20 ALXO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $171.1M $177.9M -$6.7M WHWK /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ALXO REV WHWK REV ALXO GROSS % WHWK GROSS % ALXO FCF WHWK FCF
FY 2025 $291.3M $7.1M — 89.4% -$84.4M -$98.0M
FY 2024 $398.9M $26.0M — 88.4% -$122.4M -$61.2M
FY 2023 $476.8M $24.4M — — -$130.4M -$59.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALXO // BETA —
WHWK // BETA —